NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS (Tables)

3 Months Ended

Mar. 31, 2022

Earnings Per Share [Abstract]

SCHEDULE OF EARNINGS PER SHARE, BASIC AND DILUTED

The following tables present reconciliations for the numerators and denominators of basic and diluted net loss per share:

	For the Three Months Ended March 31,
Numerator:	2022			2021
Net loss, primary	$	(3,771	)	$	(17,410	)
Less: gain from change in fair value of warrant liabilities		(4,694	)		(755	)
Net loss, diluted	$	(8,465	)	$	(18,165	)

	For the Three Months Ended March 31,
Denominator:	2022		2021
Basic weighted average number of common shares(1)		84,113,385		76,158,275
Potentially dilutive effect of warrants		5,285,876		237,803
Diluted weighted average number of common shares		89,399,261		76,396,078

(1) In December 2020 and January 2021, the Company sold pre-funded warrants to purchase up to 5,238,043 and 2,420,910 shares of common stock, respectively. The shares of common stock associated with the pre-funded warrants are considered outstanding for the purposes of computing earnings per share prior to exercise because the shares may be issued for little or no consideration, are fully vested, and are exercisable after the original issuance date. The pre-funded warrants sold in December 2020 and January 2021 were exercised in January 2021 and included in the denominator for the period of time the warrants were outstanding.

SCHEDULE OF ANTI-DILUTIVE POTENTIAL SHARES OUTSTANDING ACTIVITY

The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect:

	For the Three Months Ended March 31,
	2022		2021
Stock options		5,310,696		6,081,710
Restricted stock		4,351,355		3,061,070
Common stock warrants		1,667,700		10,223,233
Shares committed under ESPP		48,085		58,806